Hikal Past Earnings Performance
Past criteria checks 3/6
Hikal's earnings have been declining at an average annual rate of -2.7%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 6% per year. Hikal's return on equity is 6.3%, and it has net margins of 3.9%.
Key information
-2.7%
Earnings growth rate
-2.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 6.0% |
| Return on equity | 6.3% |
| Net Margin | 3.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Hikal makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 18,158 | 716 | 2,434 | 0 |
| 30 Sep 23 | 19,084 | 819 | 2,453 | 0 |
| 30 Jun 23 | 20,323 | 942 | 2,389 | 0 |
| 31 Mar 23 | 20,230 | 784 | 2,252 | 0 |
| 31 Dec 22 | 19,801 | 631 | 2,230 | 0 |
| 30 Sep 22 | 19,544 | 819 | 2,128 | 0 |
| 30 Jun 22 | 18,647 | 1,011 | 1,985 | 0 |
| 31 Mar 22 | 19,427 | 1,605 | 2,082 | 0 |
| 31 Dec 21 | 19,728 | 1,907 | 1,958 | 0 |
| 30 Sep 21 | 19,216 | 1,858 | 1,838 | 0 |
| 30 Jun 21 | 18,245 | 1,687 | 1,704 | 0 |
| 31 Mar 21 | 17,204 | 1,331 | 1,681 | 0 |
| 31 Dec 20 | 15,670 | 1,067 | 1,658 | 0 |
| 30 Sep 20 | 15,077 | 948 | 1,632 | 0 |
| 30 Jun 20 | 14,569 | 742 | 1,603 | 0 |
| 31 Mar 20 | 15,073 | 844 | 1,604 | 0 |
| 31 Dec 19 | 15,858 | 933 | 1,672 | 0 |
| 30 Sep 19 | 15,934 | 943 | 1,646 | 0 |
| 30 Jun 19 | 16,672 | 1,124 | 1,595 | 0 |
| 31 Mar 19 | 15,896 | 1,031 | 1,388 | 0 |
| 31 Mar 18 | 12,961 | 772 | 1,300 | 0 |
| 31 Mar 17 | 10,139 | 677 | 1,189 | 0 |
| 31 Mar 16 | 9,245 | 412 | 1,111 | 0 |
| 31 Mar 15 | 8,705 | 404 | 919 | 0 |
| 31 Mar 14 | 8,279 | 639 | 1,186 | 0 |
Quality Earnings: 524735 has high quality earnings.
Growing Profit Margin: 524735's current net profit margins (3.9%) are higher than last year (3.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524735's earnings have declined by 2.7% per year over the past 5 years.
Accelerating Growth: 524735's earnings growth over the past year (13.5%) exceeds its 5-year average (-2.7% per year).
Earnings vs Industry: 524735 earnings growth over the past year (13.5%) did not outperform the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 524735's Return on Equity (6.3%) is considered low.